<DOC>
	<DOCNO>NCT02339805</DOCNO>
	<brief_summary>This prospective descriptive monocentric study whose purpose describe clonal evolution mutational pattern cfDNA cohort patient Diffuse Large B-Cell Non-Hodgkin Lymphomas ( DLBCL ) , standard treatment</brief_summary>
	<brief_title>Assessment Minimal Residual Disease DLBCL From Cell-free Circulating DNA NGS</brief_title>
	<detailed_description>To determinate describe clonal evolution , 30 DLBCL case available matched tumor DNA plasma collect analyzed routinely applicable next generation sequencing ( NGS ) time diagnosis , mid treatment , end treatment 12 month diagnosis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Age 18 year old With diagnosis formally establish DLBCL transform straightaway follicular lymphoma 3B grade follicular lymphoma Burkittlike lymphoma Eligible treatment immunochemotherapy like RCHOP , RACVBP RCHOP like First line treatment Being able benefit standard extension assessment ( Fluorine18 fluorodeoxyglucose positron emission tomography ( 18FFDGPET ) bone marrow biopsy bone marrow aspiration ) Written informed consent Tumor biopsy use diagnosis available Patient receive polychemotherapy like RCHOP , RACVBP , RCHOP like Patient benefit standard extension assessment followup Fluorine18 fluorodeoxyglucose positron emission tomography ( 18FFDGPET ) Pregnant breastfeed woman Guardianship , curatorship Patient follow medical procedure study geographic , social , psychological , linguistic physical reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Minimal residual disease , NGS , NHL , DNA sequence</keyword>
</DOC>